• Revenue up 9.3% to $252.9m
• EBITDA up 210.0% to $35.1m
• EBIT up 121.1% to $11.6m
• Acquisition of Capitol Health Limited completed on 20 December 2024

Integral Diagnostics Limited reported a 9.3% increase in revenue to $252.9m and a 210.0% increase in EBITDA to $35.1m for the first half of FY25. The company's EBIT increased by 121.1% to $11.6m. On a standalone basis, the group achieved solid revenue growth of 7.8% driven by Medicare indexation, growth in patient volumes, and continued favorable mix impact. The company's organic operating revenue in Australia grew 8.4%, while in New Zealand it grew 6.6% on a constant currency basis. Capital expenditure, excluding Capitol, totaled $26.9m, with $14.8m relating to growth initiatives. The company completed the acquisition of Capitol Health Limited on 20 December 2024, and the financial results from Capitol's operations from this date to 31 December 2024 are included in the consolidated financial statements. The company's net debt increased by $88.7m to $298.7m, driven by the assumption of debt from Capitol. The company declared a fully franked interim dividend of 2.5 cents per share, with the Dividend Reinvestment Plan available for participation.

The company expects to realize at least $10.0m in projected synergies from the merger with Capitol Health Limited.

The company is focused on executing on the following drivers of its strategy to grow its business: the IDX and Capitol merger integration, driving organic earnings growth, accelerating the use of teleradiology, digital and AI, driving its environmental, social and governance (ESG) strategy, and leading through its values.